stockrowDecoy Therapeutics Inc
DCOY Healthcare Biotechnology
- Revenue
- −84.6%
- EPS
- +94.5%
- Free cash flow
- −212.5%
Quarter to June 2026, against a year earlier
Follow DCOY
Alert me
Decoy Therapeutics Inc (DCOY) EV/Sales
As of 6 November 2026, Decoy Therapeutics Inc (DCOY) trades at a EV/Sales of −3.5×. Over the past ten years it has ranged from −7.3× (September 2018) to 79.1× (March 2018); the current reading is higher than 7% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2021 | −1.9× | — |
| FY2020 | 1.6× | (55.58%) |
| FY2019 | 3.6× | (28.62%) |
| FY2018 | 5.0× | (78.27%) |
| FY2017 | 23.1× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | −1.9× | — |
| Dec 2021 | −1.9× | — |
| Jun 2021 | 3.2× | 86.79% |
| Mar 2021 | 1.7× | 6.12% |
| 19 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AFMDQ Affimed N.V. compare | −19.2× |
| DCOY Decoy Therapeutics Inc | −3.5× |
| EOCN Eocene Ltd. compare | −3.1× |
| CLDI Calidi Biotherapeutics, Inc. compare | n/m |
| NRSN NeuroSense Therapeutics Ltd. compare | n/m |
| JUNS Jupiter Neurosciences, Inc. compare | n/m |
| BCAB BioAtla, Inc. compare | 0.7× |
| KALA KALA BIO, Inc. compare | 8.0× |
| BIORQ Biora Therapeutics, Inc. compare | 67.4× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)